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1. Introduction 
In its most simplistic sense, gene therapy involves the delivery and expression of DNA by 
target cells so as to produce a therapeutic protein. In the case of RNA interference (RNAi), it 
is to shut off or silence the expression of a particular target protein. In order to exert its 
effects, the nucleic acid must first reach its intended site of action. DNA molecules 
(frequently as plasmids, which are circularised DNA) have to gain nuclear entry to access 
the transcription machinery. Conversely, RNAi molecules such as small interfering RNA 
(siRNA), short hairpin RNA (shRNA) and micro RNA (miRNA) will need to accumulate 
within the cytoplasm, although shRNA-encoding plasmids will require prior nuclear access 
before transcription into shRNA. However, if administered alone, a great majority of the 
nucleic acids will be degraded en route, leading to a lost of therapeutic potential. This then 
necessitates the development of vectors that protect and deliver nucleic acids to their target 
site. Arguably, it is the lack of safe and efficient delivery systems, rather than suitable 
therapeutic molecules that is limiting the success of gene therapy.  
In this chapter, we start by examining how issues at the cellular level have shaped the 
design of modern, multifunctional vectors. We then briefly review the various types of gene 
delivery system, focusing on peptides as a promising class of non-viral vector. We will 
concentrate on the delivery of plasmids since the phenomenon of RNAi is relatively recent 
(Fire et al., 1998). As such, many strategies for RNAi delivery are adapted from DNA 
delivery technology. 
2. Intracellular barriers in gene therapy: Problems and potential solutions 
Ensuring the arrival of a plasmid at its site of action in a transcriptional state is the entire 
aim of gene delivery systems. However, plasmids face a constant threat of being degraded. 
The challenge begins as soon as they are introduced into the extracellular milieu (Figure 1). 
In most experimental setups, cells/tissues are maintained at 37°C in serum-supplemented 
medium where serum nucleases can extensively damage a naked plasmid. The plasmid 
therefore needs protection. Next, the plasmid needs to be internalised. However, both DNA 
(phosphate groups within the backbone) and plasma membrane (glycoproteins with their 
sialic acid groups, glycerophosphates with their phosphate groups and proteoglycans which 
contain sulphate groups) are negatively charged. Electrostatic repulsion then ensures that 
there is little chance of the plasmid being naturally taken up by a cell.  
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Fig. 1. Chronological sequence of events and challenges that a plasmid faces during its 
treacherous journey towards the nucleus. 1) A naked plasmid is susceptible to degradation 
by nucleases and is likely to be repelled from the plasma membrane. 2) Assuming successful 
endocytosis, the plasmid has to avoid trafficking into lysosomes where it will be degraded. 
3) The plasmid has to escape into the cytoplasm. 4) It now has to diffuse through the viscous 
cytoplasm towards the nucleus while avoiding degradation and penetrate the nuclear 
membrane. 5) Transcription into mRNA can then occur if the plasmid is still intact. 
For these reasons, gene delivery systems are frequently designed to be cationic in character 
and this fulfils several functions. First, the carrier can use its positive charges to mask the 
negative charges on the plasmid and package itself as a carrier/DNA complex with an 
overall positive charge. As expected, positively charged particles are internalised much 
more readily, as confirmed by an elegant study using PRINT (Particle Replication In Non-
wetting Templates) technology to fabricate particles with exquisite control over their size, 
shape and surface charge (Gratton et al., 2008b). By keeping size and shape constant, 
positively charged particles were found in 84% of cells after an hour of incubation compared 
to the <5% uptake of negatively charged particles, proving that surface charge alone can 
influence uptake dramatically. Second, due to a charge screening effect, the macromolecular 
plasmid is collapsed (or condensed) into a compact structure more amendable for cellular 
uptake. This condensing process was clearly demonstrated using transmission electron 
microscopy which showed an elongated plasmid (long-axis diameter of ~470 nm) being 
compacted into tight, 80-100 nm toroid-shaped complexes by polylysine carriers (Wagner et 
al., 1991). Third, the carrier protects its cargo against degradation by nucleases, presumably 
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by steric obstruction. This was shown by first exposing the complexes to DNase and then 
using gel electrophoresis to validate the physical integrity of the plasmid upon its release 
from the carrier. Control plasmids that were unprotected gave no bands in the subsequent 
gel electrophoresis experiment.      
A problem with cationic carriers is that negatively charged serum protein can be non-
specifically bound. As a result, targeting signals on the carrier can become blocked or 
complexes can start to aggregate. Reducing or removing serum from the media during in 
vitro transfection can mitigate such effects and improve transfection (Moore et al., 2009; 
Moulton et al., 2004). However, this strategy fails during in vivo experiments where serum 
proteins are unavoidably present. Another approach is to mix DNA and carrier in precise 
stoichiometric ratio so as to result in electro-neutral complexes (Funhoff et al., 2005). Along 
similar lines, zwitterionic (McManus et al., 2004) or anionic (Liang et al., 2005) lipids have 
been proposed in which binding between carrier and plasmid is dependant on hydrophobic 
forces and the presence of divalent cations such as Ca2+, Zn2+ and Mg2+ to screen the 
disruptive repulsion between like charges. Neutral water-soluble polymers such as 
polyvinyl alcohol (PVA) and polyvinyl pyrolidone (PVP) similarly exploit non-electrostatic 
forces such as hydrogen bonding and van der Waal’s attraction to condense plasmids (Park 
et al., 2006). These particles are however less popular because the lack of positive charge is 
expected to adversely impact cellular uptake. The PEGylation of carriers is another option. 
PEGylation refers to the surface decoration of carriers with flexible chains of polyethylene 
glycol (PEG), which is a highly hydrophilic polymer capable of making a surface less 
susceptible to protein adsorption (Duncan, 2006). Having said that, a major concern is that 
PEGylation obstructs the positive charges, resulting in carriers which are less efficient in 
DNA binding and transfection (Lin et al., 2008; Meyer et al., 2008). Moreover, while 
PEGylated drug formulations are already in clinical use, PEG is non-biodegradable and its 
chronic use may be a concern (Urakami & Guan, 2008). 
The positive charges on cationic carriers have also been implicated in the formation of pores 
on the membrane, leading to cytotoxicity (Rimann et al., 2008). The observation that 
carrier/DNA complexes are less toxic to the cells compared to the carrier alone can be 
interpreted as partial evidence that charge compensation on the carrier may be a reason, 
albeit a non-exclusive one, for the reduced toxicity (Niidome et al., 1997). However, the 
exact mechanism is not totally clear. It may be due to the high rate of uptake of cationic 
carriers – and not the positive charges per se – that is to blame for pore formation. Herein lies 
a dilemma of the gene therapist: a high rate of internalisation can increase transfection 
efficiency but is also frequently paralleled by toxicity (Gabrielson & Pack, 2006; Pouton & 
Seymour, 2001). Fortunately, cells do have membrane repair mechanisms. One example is 
the membrane repair response (MRR) where the influx of Ca2+ ions directs lysosomes to 
donate their vesicular membrane in a concerted effort to plug the hole (Palm-Apergi et al., 
2009). As always, the challenge is to strike a fine balance between two counter-acting events.  
Assume the plasmid has been successfully taken up by a cell via endocytosis and now 
resides within an endosome. Another degradative fate awaits as endosomes eventually 
acidify into lysosomes and activate a broth of acid hydrolases capable of degrading nucleic 
acids. For this reason, a high rate of uptake may not necessarily translate into high 
transfection efficiency if, for example, most of the plasmids are degraded in lysosomes 
(Lundin et al., 2008). To avoid degradation, the plasmid/carrier complex will need to escape 
from the confines of the endosome into the cytosol. A popularly cited mechanism by which 
cationic carriers can achieve this is the proton-sponge hypothesis, so called because it relies 
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on the buffering capability of the carrier to absorb H+ ions and thus function as a proton 
sink. This model assumes that as the H+-ATPase endosomal membrane pump injects 
protons into the vesicle during acidification, a build-up of positive charges will result due to 
the ability of the carrier to protonate and absorb the protons. This then triggers a 
concomitant influx of compensatory negative ions (e.g., Cl-) and water, leading to the 
osmotic swelling of the vesicle and its eventual rupture. Consistent with this line of 
argument, carriers must thus contain chemical groups that are capable of undergoing 
protonation within the pH range of the endo/lysosomal transition, i.e., a pKa of 7 to 4. This 
has motivated investigators to design carriers with a large buffering capacity. The polymer 
polyethylenimine (PEI), for instance, has a combination of protonated amines to bind 
plasmids at pH 7 and a stockpile of unprotonated amines that can still undergo protonation 
during the endo/lysosomal transition (Boussif et al., 1995). As such, PEI has a large 
buffering capacity and this feature is frequently cited as a main reason for PEI’s status as 
one of the most efficient non-viral vector commercially available for in vitro transfection 
(Putnam, 2006).  
Another common strategy to promote endosomal escape is to coincubate cells with a 
lysosomotropic agent such as chloroquine. Traditionally used as an anti-malaria drug, 
chloroquine is also a weak base capable of buffering the acidification of endosomes. In 
reality, however, chloroquine is pleiotropic in nature – besides its lysosomotropic property, 
chloroquine has been reported to be able to aid in the release of plasmid from its carrier and 
also to inhibit DNase activity (Yang et al., 2009) – and its actual mechanism of action 
remains controversial. Nevertheless, chloroquine does generally improve the transfecting 
capability of many carriers (Pouton & Seymour, 2001). A caveat, though, is that chloroquine 
at the dose normally used (100 μM) is toxic to cells (Wadia et al., 2004; Zauner et al., 1998). 
Glycerol is another agent reported to augment transfection due to its ability to weaken and 
make vesicular membrane more susceptible to disruption (Zauner et al., 1997). Interestingly, 
the more obvious effect of adding glycerol – its osmotic property – was ruled out as the 
main cause of vesicle escape. Finally, carriers can be functionalised with membrane-
disruptive peptides, a strategy which will be reviewed in later sections. 
The proton-sponge hypothesis is the most commonly cited explanation to account for the 
positive correlation between increased buffering capacity and transfection ability. It is hence 
easy to overlook that no study has provided any convincing evidence in direct support of its 
mechanism (Won et al., 2009). In fact, discrediting observations exist. For instance, it was 
reported that ammonium sulphate, also a weak base and should theoretically be able to 
provide buffering effects, does not boost transfection (Pouton & Seymour, 2001). Recent 
calculations have also revealed that the amount of strain that lipid vesicles can withstand 
before rupture is significantly larger than that which can be induced by endosomal 
buffering (Won et al., 2009). This suggests that the proton-sponge hypothesis can at best 
contribute, but cannot be the only cause of endosomal escape. Moreover, increased buffering 
and endosomal escaping properties do not always produce an accompanying increase in 
transfection (Akita et al., 2010; Moore et al., 2009). This implies that, while important, 
cytosolic access is not the only bottleneck of the transfection process. Further, it has to be 
pointed out that of the multiple pathways which a cell can use for internalisation, only the 
clathrin-mediated one is widely-accepted to involve vesicle acidification (Won et al., 2009; 
Zauner et al., 1997). Vesicle acidification is, of course, an inherent requirement of the proton-
sponge hypothesis but whether vesicles from other pathways acidify is equivocal. Some 
researchers believe that macropinocytosis (Akita et al., 2010; Pelkmans & Helenius, 2002) 
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and caveolae-mediated endocytosis (Lundin et al., 2008; Sahay et al., 2010) produce vesicles 
that do not undergo acidification, while others claim that macropinosomes do acidify 
(Räägel et al., 2009; Wadia et al., 2004). Furthermore, is it safe to assume that vesicles which 
do not acidify remain distinct from endo/lysosomes? On this, opinion is also polarised, with 
some claiming that caveosomes (Pelkmans & Helenius, 2002; Sahay et al., 2010) and 
macropinosomes (Wadia et al., 2004) remain distinct from endo/lysosomes; and others 
arguing that vesicles from different pathways can eventually interact (Sahay et al., 2010). 
Thus, the proton-sponge hypothesis even if true, may not always be relevant and on top of 
that, definitive trafficking studies of the various modes of uptake are required.  
In the cytosol, the plasmid continues its migration towards the nucleus. Current dogma 
suggests that this proceeds via passive diffusion and that nuclear localisation is a hit-or-miss 
event. The viscous cytosolic environment makes diffusion extremely inefficient. The 
diffusion coefficient of bovine serum albumin (BSA) in human fibroblasts, for example, is 
about 70× lower than in buffer (Wojcieszyn et al., 1981). Protecting the plasmid during 
migration is also important as cytosolic nucleases restrict the half life of naked DNA to 
about 90 minutes (Belting et al., 2005).  
During migration, another feature of the carrier becomes important – the release of its 
plasmid cargo. To undergo transcription, the plasmid must first be unpackaged from its 
carrier and the trick here, is one of timing. A plasmid that gets released too early will risk 
degradation while one that binds too strongly is not accessible for transcription. For this 
reason, lower molecular weight chitosan transfects better because their higher molecular 
weight counterpart interacts too strongly with their plasmid cargo (Koping-Hoggard et al., 
2004). Another example involves PEI, where acetylation of its polymeric chains (which 
removes the amines) reduced both its buffering capacity and binding strength, but 
improved its transfection (Gabrielson & Pack, 2006). This suggests that vector unpackaging 
can indeed be a rate-limiting step and a carrier that binds in moderation is ideal. 
Fluorescence resonance energy transfer (FRET) is a powerful technique to study the process 
of vector unpackaging. It depends on the excitation of an acceptor dye by a donor dye in 
close physical proximity, which is the case when the plasmid is being tightly condensed. 
Using FRET, plasmid-release in the perinuclear region has been observed; alternatively, the 
plasmid/carrier can enter the nucleus as an associated complex (Seow et al., 2009).    
Nuclear entry is believed to be achieved in two ways: either via the ~10 nm wide nuclear 
pores or during mitosis when the nuclear envelope momentarily disintegrates (Luo & 
Saltzman, 2000a). The latter appears to be a more efficient method for the large-scale 
accumulation of complexes. It further provides a possible explanation for why amitotic cells 
or primary cells which proliferate slower are more difficult to transfect than cancer-derived 
cell lines. A dilution effect after mitotic cell division also accounts for the transient nature of 
gene expression mediated by non-integrating vectors. Having said that, mitosis is not a pre-
requisite (Won et al., 2009) as amitotic cells have been successfully transfected – it merely 
provides a convenient window of opportunity for nuclear entry. A proposed method to 
improve nuclear penetration is to attach a nuclear localisation signal (NLS) to the carrier. 
The quintessential example of a NLS is the short peptide sequence corresponding to the 
Simian virus 40 (SV40) T antigen. However, responses regarding the benefits of including a 
NLS have been mixed, with some investigators (Trentin et al., 2005) more convinced than 
others (Zauner et al., 1998). A key issue pointed out was that studies involving the use of 
NLS failed to examine the effect of including a NLS on nuclear import per se (Lam & Dean, 
2010). Instead, reporter gene expression was frequently used as a proxy and an improved 
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expression was simply accepted to be due to the inclusion of NLS. Given that most NLS are 
cationic, it is debatable if the observed increase in transfection is strctly the result of 
improved nuclear import per se, or due to other non-specific effects such as enhanced 
plasmid association and uptake. Moreover, the fact that a NLS can be sterically hindered by 
plasmids upon binding also contradicts the requirement of NLS to be freely accessible for 
interaction with importins, the nuclear entry regulating proteins. 
In light of the many obstacles that nucleic acids and their carriers have to surmount, it is 
perhaps understandable that less than 10% of the pool of plasmids that made it into a cell 
will go on to accumulate in the nucleus (Lam & Dean, 2010). The challenge is to design a 
multifunctional vector that can address the issues highlighted above and yet, remain safe to 
use in a human body. 
3. Overview and classification of gene delivery systems 
3.1 Physical systems 
Gene delivery systems can be classified based on their means of achieving transfection 
(Figure 2). There are systems that utilise physical forces, mostly with the aim of disrupting 
the plasma membrane, to facilitate nucleic acids delivery. For instance, electroporation and 
sonoporation (Frenkel, 2008) uses electrical and sonication forces respectively to transiently 
compromise the plasma membrane. The ballistic gene gun method, on the other hand,  
 
 
Fig. 2. The different classes and examples of gene delivery systems. This chapter will 
concentrate on peptide-derived vectors. 
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directly shoots DNA-coated metal particles (frequently gold) into cells (Merediz et al., 2000). 
Expectedly, such aggressive methods can irreversibly damage the cell membrane and cause 
widespread cell death. Scrape loading, first described in 1984, requires the forceful scraping 
of cells attached to their culture dishes, thereby creating pores on their membranes for 
plasmid entry (McNeil et al., 1984). This technique, however, is only applicable to adherent 
cells. The osmotic lysis of pinosomes was proposed in 1982 and requires that cells capable of 
pinocytosis be initially exposed to a hypertonic medium of sucrose, PEG and the plasmid of 
interest (Okada & Rechsteiner, 1982). Subsequent exchange to a hypotonic medium then 
released the pinosomal content. Although cells are constitutively capable of pinocytosis, 
such wild fluctuations in osmotic conditions can cause cell death. Finally, microinjection 
refers to the piecemeal injection of plasmids directly into the cell. This technique, while 
relatively gentle, is extremely laborious. As such, it is prone to failure and the number of 
cells that can be processed is limited.       
3.2 Viral vectors 
There are systems that function as particulate carriers by ferrying nucleic acids into or near 
to their site of action. Such systems can be viral or non-viral in nature. Viral vectors such as 
adenovirus, adeno-asociated virus (AAV), human immunodeficiency virus (HIV), equine 
infectious anaemia virus (EIAV), herpes simplex virus (HSV) and murine leukaemia virus 
(MLV) have been used and comprehensively reviewed elsewhere (Kay et al., 2001). The 
prime advantage of viral vectors is their transfection efficiency which has benefitted from 
centuries of selective evolutionary pressure. As a result, viruses are several orders of 
magnitude more efficient than non-viral vectors (Kircheis et al., 1997) and account for about 
70% of all clinical trials involving gene therapy so far (Won et al., 2009). A recent success for 
viral gene therapy involved the use of lentiviruses to deliver a correct copy of a therapeutic 
gene to an adult patient suffering from ǃ-thalassaemia (Cavazzana-Calvo et al., 2010). Such 
patients suffer from defective haemoglobin production and require chronic blood 
transfusion for survival. Upon reinfusing the patient with his own bone-marrow 
haematopoietic stem cells that had earlier been transduced ex vivo, the patient became 
transfusion free 1 year after treatment and has been doing well, according to the most recent 
report at 33 months after treatment. The longer-term outcome, of course, remains to be seen.  
Having said that, investigators have not abandoned all forms of non-viral research as there 
are limitations in the use of viral vectors. For example, the technical difficulty of scaling up 
virus production compliant to good manufacturing practices (GMP) may prevent such 
therapy from being cheaply accessible (Sheridan, 2011). The size of the construct that can be 
delivered is also limited. Above all, toxicity and immunogenicity (reviewed by Nayak & 
Herzog, 2010) provoked by the viral vectors can and have brought clinical trials to 
premature ends. Repeated administration is also not possible if the body has mounted a 
systemic immune response. The danger of viral gene therapy was first illustrated about a 
decade ago by the death of Jesse Gelsinger (Hollon, 2000). Researchers were using 
experimental adenoviruses to correct his partial ornithine transcarbamylase deficiency 
affecting the ability of his body to metabolise nitrogen. Unfortunately, the systemic 
inflammatory response syndrome was triggered and he succumbed, rather rapidly, to 
multiple organ failure. In another high-profile example, stem cells transduced ex vivo with 
MLV were used to treat children suffering from X-linked severe combined 
immunodeficiency (Hacein-Bey-Abina et al., 2003). However, MLV is an integrating 
retrovirus and can cause insertional mutagenesis, which is a phenomenon where random 
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viral integration can trigger the activation of an oncogene or disrupt genes with tumor-
suppressive properties. Consequently, several patients became leukemic and at least one has 
died so far (Sheridan, 2011). More recently, retroviruses were also used to treat two patients 
diagnosed with X-linked chronic granulomatous disease which affected the ability of their 
phagocytes to clear bacterial infections (Ott et al., 2006). Insertional mutagenesis was again 
responsible for a clone of cells whose genes responsible for growth were activated, 
prompting fears that such cells may turn cancerous. Having said that, viral gene therapy is 
not expected to be perfect and its success should be assessed relative to existing treatments. 
Nonetheless, researchers have not completely mastered the use of viruses and there is still a 
need for alternative non-viral vectors with safer profiles. 
3.3 Non-viral vectors 
Diethylaminoethyl (DEAE)-dextran and calcium phosphate (CaPO4) were two of the earliest 
systems popular in the 1970s and 80s. DEAE-dextran has a cationic polysaccharide backbone 
and one of the earliest reports in 1965 used this polymer in a 1:1 mixture with nucleic acids 
to transfect rhesus monkey kidney cells (Vaheri & Pagano, 1965). Authors of this study also 
insightfully commented that DEAE-dextran, like histones, could bind and protect nucleic 
acids from degradation. Although these are now fundamental concepts in modern carrier 
design, it may not have been as obvious in the past. The co-precipitation of CaPO4 with 
DNA was first described in 1973, when it was observed that Ca2+ (not Mg2+ or Na+) and 
PO42- ions, at high enough concentrations, could enhance DNA uptake by cells (Graham & 
Eb, 1973). This technique was further shown to be sensitive to pH, amount of DNA used and 
even the level of CO2 in the incubator (Chen & Okayama, 1987). Using an optimised 
protocol, CaPO4-mediated transfection achieved up to 50% efficiency with a murine L cell 
line (Chen & Okayama, 1987). 
Chitosan is a polysaccharide obtained by the deacetylation of chitin, an exoskeletal 
component of crustaceans. Each deacetylation site contains a primary amine (pKa~6.5) 
which allows chitosan to bind nucleic acids. The degree of deacetylation also determines its 
biodegradability and transfection efficiency. Chitosan was first described as a plasmid 
carrier by Mumper and colleagues in 1995 and is known to be biocompatible, mucoadhesive 
and virtually non-toxic (MacLaughlin et al., 1998). As such, chitosan has been evaluated in 
rabbits, although reporter gene expression in that study was low (MacLaughlin et al., 1998). 
Strong interactions between high molecular chitosan and DNA were blamed for the overly-
stable complexes that could not release their plasmid cargos. Using lower molecular weight 
chitosan, in vitro transfection efficiency was improved by up to 24 fold (Koping-Hoggard et 
al., 2004). Adding histidine (pKa~6) residues to chitosan further improved buffering capacity 
and overall transfection efficiency (Chang et al., 2010). Recently, it was also shown that the 
introduction of thiol groups in N,N,N-trimethylated chitosan improved its efficiency as a 
siRNA carrier (Varkouhi et al., 2010). 
Red blood cells (RBC) were used for the delivery of macromolecules before liposomes 
became popular. To function as carriers, RBC were first loaded up with the macromolecule 
under hypotonic conditions to induce mild lysis. A fusogen was then used to cause fusion 
with target cells. Using this technique, thymidine kinase and BSA were introduced into 3T3-
4E mouse cells using Sendai virus as a fusogen (Schlegel & Rechsteiner, 1975). In another 
study, horseradish peroxidase (HRP) and immunoglobulins (IgG) were delivered into cells 
expressing hemagglutinin derived from influenza virus by exploiting the fusogenic activity 
of hemagglutinin under mildly acidic conditions (Doxsey et al., 1985). Fluorescent IgG and 
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BSA were also delivered into human fibroblast cells using PEG as a fusogen (Wojcieszyn et 
al., 1981). Dehydration may play a role in PEG-mediated fusion and intriguingly, 
purification by recrystallisation removed the fusogenic ability of PEG, suggesting that other 
ingredients in commercial PEG was essential (Wojcieszyn et al., 1983).    
Plasmids were initially delivered by synthetic liposomes using concepts adapted from RBC 
technology. In an early study, plasmids were encapsulated within anionic liposomes and 
fused with tobacco mesophyll protoplasts using PEG (Deshayes et al., 1985). Since 1987, 
however, surface binding became popular when liposomes made of N-[1-(2,3,-
dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) were synthesised for the 
first time (Felgner et al., 1987). DOTMA contains cationic quaternary ammonium groups 
which can be used for DNA binding. Lipofectin®, the prototypical lipid formulation and a 
workhorse for transfection experiments today, is a 1:1 mixture of DOTMA and the neutral 
lipid, dioleoyl phosphatidylethanolamine (DOPE). In this formulation, DOPE functions as a 
fusogen to aid cellular uptake. Several other formulations of liposomes have been reported. 
Gao and Huang prepared liposomes made out of DOPE and a novel cationic cholesterol 
derivative, 3β-[N-(N’,N’-dimethylamino)ethane-carbamoyl] cholesterol (DC-chol), and used 
it to transfect several cell lines with high efficiency (Gao & Huang, 1996). A mixture of N′,N′-
dioctadecyl-N-4,8-diaza-10-aminodecanoylglycine amide (DODAG) and DOPE was also 
proposed to be a novel liposomal formulation that is good for both DNA and siRNA 
delivery (Mével et al., 2010). In another study, the cationic lipid 1,2-dilinoleyloxy-3-
dimethylaminopropane (DLinDMA) was used as a starting template and systematically 
modified to yield an optimised construct (Semple et al., 2010). Although toxicity remains 
one of the chief complaints, liposomes are definitely one of the most successful non-viral 
vectors around. Already, several sustained-release liposomal drug formulations have been 
approved for human use and thermosensitive liposomes are being evaluated in clinical trials 
(Hossann et al., 2010). Lipids also dominate in gene therapy trials aimed at using non-viral 
vectors to treat cystic fibrosis (Griesenbach & Alton, 2009). 
An advantage of polymeric carriers is that they offer so much structural diversity that their 
potential should, theoretically, be limited only by the imagination of chemists. Two of the 
more archaic examples including PVP and PVA have been mentioned. Poly(D,L-lactic-co-
glycolic acid) (PLGA), a polymer originally developed for controlled drug release, has also 
been used to encapsulate plasmids for delivery (Wang et al., 1999). Most polymeric carriers, 
however, are cationic in nature. Dendritic poly(amido amine) (PAMAM) which contained 
primary amines for DNA binding was further decorated with PEG and sugars (Wood et al., 
2005) or peptide (Wood et al., 2008) for targeting purposes. Linear PAMAM was 
functionalised with disulfide bonds to make the polymer biodegradable and various 
chemical side-groups were attached to test for its impact on transfection efficiency (Lin et al., 
2007). A large library of poly(ǃ-amino ester)s has been synthesised and systematically 
screened for transfection efficiency (Green et al., 2006). The effects of molecular weight and 
charge density of polyphosphoramidates (PPA) on DNA binding and buffering capacity 
have been reported (Ren et al., 2010). A series of novel enzyme-degradable polycarbonates 
(PC) with various aliphatic side-chains attached were prepared and shown to effectively 
transfect cells with virtually no toxicity (Seow & Yang, 2009a). Poly(2-(dimethyl-
amino)ethylmethacrylate) (PDMAEMA) was also shown to transfect cells with high 
efficiency (Lin et al., 2008). Indeed, there are so many other classes of polymers being 
developed that it is impossible to do all justice with this paragraph. Nonetheless, amongst 
all, the most notable polymer must be PEI. PEI was first developed in 1995 (Boussif et al., 
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1995) and is frequently used in its branched, high molecular weight (usually 25 kDa) form. 
Together with liposomes, they are widely acknowledged to be the best non-viral vectors 
currently available (Putnam, 2006) and frequently serve as standards to which other novel 
carriers are referenced. A key feature of PEI is that nitrogen (in a mixture of primary, 
secondary and tertiary amines) accounts for a third of its molecular weight. Since different 
classes of amines possess characteristic pKa, this ensures that not all the nitrogen will be 
protonated at a given pH. Furthermore, the proximity of the nitrogen atoms also means that 
a protonated amine can suppress the protonation of its neighbours due to the energetic 
penalty that gets incurred by situating like charges adjacent to one another (Suh et al., 1994). 
This blend of protonated and yet-to-be protonated amines is then suggested to endow PEI 
with its strong DNA binding and buffering abilities. The intracellular trafficking properties 
of PEI/DNA complexes has been studied (Godbey et al., 1999) and targeting moieties such 
as mannose (Diebold et al., 1999) and transferrin (Kircheis et al., 1997) were also coupled 
onto PEI. However, two of the main problems of PEI are its toxicity and non-
biodegradability. In response to the latter, PEI was functionalised with reducible disulfide 
bonds (Lee et al., 2007) or hydrolysable ester bonds (Liu et al., 2008) to facilitate 
biodegradation and at the same time, to aid its intracellular plasmid release. 
4. Peptide-derived vectors for gene therapy 
Peptide chains can be fabricated from any of the 20 naturally occurring L-amino acids, 
which are referred to by their single- or three-lettered code (e.g., R or arg for arginine). 
Peptides are thus biocompatible and often degradable. Peptide synthesis also does not 
involve harmful catalysts, which is a concern in the synthesis of some polymeric carriers. 
Furthermore, synthesis can now be automated, courtesy of advances in solid phase peptide 
synthesis, which makes the manufacturing process amendable to up-scaling. 
Before peptides were seen as proper DNA carriers, studies conducted in the 1960s with 
histones had already suggested that cationic amino acids such as lysine and arginine can 
be useful (Akinrimisi et al., 1965). Today, peptide vectors are given fanciful names such as 
“cell penetrating peptides” (CPP) or “protein transduction domains” (PTD) to celebrate 
their ability to efficiently penetrate the plasma membrane and mediate the entry of nucleic 
acids or other macromolecules. Such CPP can be derived from proteins existing in nature 
(e.g., viral proteins or venom proteins of bees and wasps) or designed de novo. There is 
little in common among CPP and the only unifying theme seems to be the significant 
presence of cationic residues (mainly lysine and arginine). Amphipathicity has been 
suggested to be another common feature. However, this is only true for most CPP – 
oligoarginine being an exception. There are two methods by which peptide vectors carry 
their cargoes. Nucleic acids are usually non-covalently (electrostatically) attached, while 
proteins and other macromolecules are typically covalently coupled (chemical cross-
linking or by plasmid fusion). The advantages of electrostatic attachment include 
convenience and the largely unaltered chemical properties of the cargo. However, charge 
interactions are non-specific and excess peptides are usually needed to completely bind 
the plasmid. On the other hand, covalent attachment requires chemical modification of 
the cargo and usually results in stable complexes which, as discussed earlier, may not be 
desirable. In the following sections, we will review the key classes of peptide vectors and 
provide non-exhaustive examples of strategies that have been used to improve their 
efficiency as vectors. 
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Peptide Sequence (single letter code) Short description 
Poly-L-lysine Kn Frequently, n = 50-400 
Tat YGRK KRRQ RRRP PQ HIV-derived, sequence 47-60 
Oligoarginine Rn Frequently, n = 7-9 
Penetratin RQIK IWFQ NRRM KWKK 3rd helix of Antennapedia homeodomain 
Tp GWTL NSAG YLLG KINL KALA 
ALAK KIL 
Galanin + mastoparan (wasp venom) 
Tp10 AGYL LGKI NLKA LAAL AKKI L First 6 residues deleted from Tp 
VP22 300-residue long sequence given in 
(Elliott & O’Hare, 1997) 
HSV-1 structural protein 
MPG GALF LGFL GAAG STMG AWSQ 
PKSK RKV 
HIV gp41 + SV40 T-antigen 
CADY GLWR ALWR LLRS LWRL LWRA Peptide carrier PPTG1-derived 
KALA WEAK LAKA LAKA LAKH LAKA 
LAKA LKAC EA  
Membrane disruptive peptide, also a 
carrier 
GALA WEAA LAEA LAEA LAEH LAEA 
LAEA LEAL AA 
Membrane disruptive peptide 
EB1 LIRL WSHL IHIW FQNR RLKW 
KKK 
Penetratin analogue  
HA2 GLFG AIAG FIEN GWEG MIDG Influenza virus hemagglutinin protein 
INF5 (GLFE AIEG FIEN GWEG nIDG)2K HA2-derived, lysine-connected dimer. n = 
norleucine 
INF7 GLFE AIEG FIEN GWEG MIDG 
WYG 
HA2-derived, monomer 
SV40 PKKK RKV Simian virus 40 T antigen NLS 
Melittin GIGA VLKV LTTG LPAL ISWI 
KRKR QQ 
Bee venom 
Table 1. The amino acid sequences of all the peptides discussed in this chapter. 
4.1 Poly-L-lysine (PLL) 
The amino acid sequence of PLL and all other peptides subsequently discussed can be found 
in Table 1. PLL is the first peptide-based vector to be studied intensively. The molecular 
weight of PLL spans a wide range and depends on the number of repeating units within a 
chain, or its degree of polymerisation (DP). For the sake of discussion, the molecular weight 
of PLL is arbitrarily classified as follows: oligolysine (DP<20), low (20≤DP<50), medium 
(50≤DP≤400) or high (DP>400). Most studies use PLL of medium molecular weight.  
PLL has been successfully employed to deliver a host of different cargos. By covalently 
coupling human serum albumin or HRP to PLL via amide bonds in a 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) catalysed reaction, proteins were delivered into 
L929 mouse fibroblasts for the first time using such a PLL-mediated strategy (Shen & Ryser, 
1978). More recently, streptavidin-conjugated quantum dots (QD) were also attached to 
biotin-tagged PLL and delivered into HeLa cells (Mok et al., 2008). However, PLL is most 
frequently used to deliver nucleic acids where the electrostatic attachment is preferred. 
Although polylysine made out of D-amino acids has been suggested to work better – 
presumably because they are more resistant to enzymatic degradation (Mitchell et al., 2000) 
– PLL continues to be favoured in transfection studies. Wu and partner provided one of the 
earliest examples of PLL being used to condense plasmids for receptor-mediated delivery 
(Wu & Wu, 1987). In that study, asialoorosomucoid (ASOR) was first covalently attached to 
PLL with N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) as a linker and then used to 
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bind a reporter plasmid. Complexes then accumulated within HepG2 cells (ASOR receptor 
positive) but not in SK-Hep1 cells (ASOR receptor negative).    
Plasmids dissociated more slowly if bound to a higher molecular weight PLL and this can 
negatively affect transfection (Schaffer et al., 2000). To facilitate plasmid release, cysteine 
residues were added to oligolysine, which was then cross-linked using disulfide bonds 
(McKenzie et al., 2000). The intention was to make use of the intracellular environment – 
which is much more reductive due to its elevated levels of glutathione (Lee et al., 2007) – to 
break down the disulfide bonds for polymer disintegration and plasmid release. The 
number of lysine, cysteine and histidine (for buffering capacity) residues used and the 
spacing and ordering between the residues were found to influence the final performance of 
the vector. Upon optimisation, some constructs transfected at levels that were comparable or 
even higher than LipofectAce, a commercial reagent used as a positive control (McKenzie et 
al., 2000). Disulfide-linked oligolysine was then further functionalised with triantennary N-
glycan signals to target hepatocytes and evaluated in vivo (Kwok et al., 2003). However, 
contrary to results in vitro, the particles were not stable enough in the reductive intracellular 
liver environment and premature plasmid release ultimately limited gene expression.  
PLL by itself is generally not considered to be an efficient vector (Meyer et al., 2008) and is 
frequently coupled with other agents. The imidazole headgroup of histidine (pKa~6) can 
provide endosomal buffering and has been added to PLL to boost transfection (Midoux & 
Monsigny, 1999). Histidine was also added onto a K15-based oligopeptide which was then 
self assembled for drug and gene co-delivery (Wiradharma et al., 2009). The HA2 subunit of 
the hemagglutinin glycoprotein present on the surface of influenza virus plays an important 
role in the endosomal escape of viruses. To do this, HA2 exhibits a pH-dependent 
membrane fusion activity. HA2 is not normally lytic at neutral pH. However, protonation of 
its acidic residues during endo/lysosomal transition triggers HA2 to adopt a more ǂ-helical 
secondary conformation. At the same time, it exposes a highly-conserved hydrophobic 
sequence which then interacts and destabilises the endosomal membrane (Wagner et al., 
1992a). To exploit this membrane-disrupting mechanism, 20 amino acids corresponding to 
the N-terminus of HA2 were attached to PLL via cysteine-mediated disulfide bonds. The HA2-
functionalised PLL was then shown to induce pH-dependent liposomal leakage (Wagner et al., 
1992a) and to augment transfection to a greater extent than the use of chloroquine (Midoux et 
al., 1993). Melittin, a major component of bee venom, is another peptide with fusogenic activity 
but unlike HA2, melittin is unresponsive to pH. As such, it remains fusogenic at pH 7 and can 
indiscriminately disrupt plasma membranes (Chen et al., 2006). To confine fusogenic activity 
within the endosomes, dimethylmaleic anhydride protecting groups were attached to mask 
the activity of melittin at neutral pH. Upon cleavage of the protecting groups under acidic 
conditions, the activity of melittin was restored (Meyer et al., 2008). This protected form of 
melittin was then coupled to PLL via a cysteine-mediated disulfide bond and the entire 
construct mediated siRNA knockdown more efficiently than PEI. Adenovirus, known to 
display pH-dependent membrane disruption as part of its infectious cycle (Curiel et al., 1991), 
has also been coupled to PLL to improve transfection efficiency. Human adenovirus type 5 
(dl312) was either biotinylated and coupled to a streptavidinylated PLL (Wagner et al., 1992b), 
or simply added as free viral particles into the culture medium to be taken up together with 
the PLL complexes (Curiel et al., 1991). In another study, chicken embryo lethal orphan virus, 
an adenovirus from chicken, was attached to PLL and augmented transfection as well as 
human adenovirus (Cotten et al., 1993).  
Various signals have also been added onto PLL to improve its uptake or target specificity. 
For instance, galactose containing an isothiocyanate group was reacted with the amine 
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groups on PLL to form a thiourea bond and used to mediate gene expression in the livers of 
rats for up to 140 days (Perales et al., 1994). Mannose and lactose were also used to target 
cell lines that have receptors for the specific sugar (Midoux et al., 1993). ASOR was coupled 
onto PLL in an EDC catalysed reaction and intravenously injected into rats (Wu et al., 1989). 
However, reporter gene expression by liver cells disappeared by day four. Transferrin was 
coupled to PLL via disulfide bonds in a SPDP-mediated reaction to increase its 
accumulation within cells (Wagner et al., 1991). Insulin was also coupled to PLL in an SPDP-
mediated reaction and used with adenovirus (biotin-streptavidin conjugated) to deliver 
plasmids into pre-implantation mammalian embryos (Ivanova et al., 1999). PEG was grafted 
onto PLL via amide bonds in an N-hydroxysuccinimide (NHS) catalysed reaction and 
helped in preventing particle aggregation (Rimann et al., 2008). Stearyl-PLL mixed with a 
low density lipoprotein was also used to condense plasmids (~600 nm) into ~100 nm 
complexes, as measured by atomic force microscopy (Kim et al., 1998). Further, the 
lipoprotein was found to be essential for efficient uptake. Finally, peptides themselves can 
serve as targeting signals. For example, a short peptide sequence (GACRRETAWACG) 
suggested to target ǂ5ǃ1 integrins was linked to K16 and mixed with Lipofectin® to transfect 
neuroblastoma cells (Lee et al., 2003). Several groups have also used the RGD motif to target 
integrins. A recent example involved RGD being linked to K16 peptides, which were then 
used with an intracellularly cleavable PEG-lipid formulation to deliver plasmids into mice 
bearing subcutaneous tumors (Tagalakis et al., 2011). The integrin-targeting signal was 
shown to be important. Upon augmentation by the enhanced permeation and retention 
effect, the complexes were mainly distributed to the tumor. 
4.2 Tat 
Full length tat has 86 amino acids (sequence 1-86) and it is a regulatory protein encoded by 
HIV-1 that transactivates viral gene expression. The ability of tat to cross cell membrane was 
initially observed by two groups independently in 1988 (Frankel & Pabo, 1988; Green & 
Loewenstein, 1988). In one study, tat was simply added to a culture of HL3T1 cells modified 
to contain an integrated copy of chloramphenicol acetyltransferase (CAT, a reporter gene) 
under the control of the HIV-1 LTR (long terminal repeat) promoter and CAT expression 
was unexpectedly detected (Frankel & Pabo, 1988). Crucially, the amount of CAT expression 
was dependent on the dosage of tat. Unlike earlier experiments, tat did not require any help 
from the scrape loading technique to enter cells. Tat 1-86 was further dissected into five 
regions and region II and III, together spanning roughly residues 38-62, were identified to 
be essential and sufficient for transactivation activity (Green & Loewenstein, 1988). Region 
III (roughly residues 49-62), in particular, was interesting and was rich in arginine and 
lysine. Furthermore, replacing the three arginines at position 55-57 with alanines drastically 
reduced transactivation activity. Tat was also observed to localise in the nucleus and 
thought to be a NLS (Green & Loewenstein, 1988). 
The region surrounding the arginine- and lysine-rich domain of tat was keenly evaluated as 
a gene carrier. Today, full length tat is seldom used and among the many truncated versions 
being studied (Table 2), tat 47-57 and 48-60 are the two most popular sequences. The in vivo 
half life of free tat 47-57 was calculated to be ~3.5 minutes (Grunwald et al., 2009) and tat 48-
60 exists as an unstructured random coil in buffer solutions or when bound to lipid vesicles 
(Caesar et al., 2006). The secondary structure of a carrier has been suggested to affect its 
membrane translocation ability. However, it remains unclear if it is better for a structure to 
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be rich in ǂ-helices or unordered. On the one hand, structures rich in ǂ-helices have been 
suggested to be more efficient in inserting themselves and crossing lipid bilayers (Almeida 
& Pokorny, 2009). This is consistent with the view that ǂ-helical structures are responsible 
for the membrane disrupting property of fusogenic peptides such as HA2 (Wagner et al., 
1992a), melittin (Chen et al., 2006) and GALA (Subbarao et al., 1987). On the other, ǂ-helices 
has also been negatively correlated with uptake (Ye et al., 2010). Instead, an unordered 
structure was preferred as it afforded the flexibility needed to adopt the most energetically 
favourable conformation during membrane translocation (Caesar et al., 2006). 
 
Entry Sequence Reference 
1 1-86 (Green & Loewenstein, 1988) 
2 1-72 (Frankel & Pabo, 1988) 
3 37-72 (Fawell et al., 1994) 
4 37-57 (Leonetti et al., 2010) 
5 43-60 (Eguchi et al., 2001) 
6 47-57 (Wang et al., 2010) 
7 48-57 (Wadia et al., 2004) 
8 48-58 (Fittipaldi et al., 2003) 
9 48-59 (Richard et al., 2005) 
10 48-60 (Eiriksdottir et al., 2010) 
11 49-57 (Saleh et al., 2010) 
12 49-60 (Astriab-Fisher et al., 2000) 
Table 2. Heterogeneity in tat sequences being reported in the literature. All sequences are 
with respect to the original sequence 1-86 in the first entry. Only one reference is provided 
for each entry, although there may be more discussed in text. 
Proteins have been delivered by tat and are usually covalently attached. Fawell and 
colleagues were the first to chemically conjugate several different proteins onto tat 37-72 
(Fawell et al., 1994). One of the model proteins used was ǃ-galactosidase (ǃ-gal), which was 
grafted onto tat using succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate 
(SMCC) as a heterobifunctional cross-linker. The ǃ-gal/tat conjugate was then intravenously 
injected into mice and found to accumulate mainly in the heart, liver and spleen. In a 
separate study, ǃ-gal/tat 47-57 conjugates were generated by plasmid fusion and injected 
intraperitoneally into mice (Schwarze et al., 1999). The conjugates were then found to be 
distributed to all tissues, even across the tight blood-brain-barrier. GFP/tat 47-57 fusion 
protein was also delivered into cells and uptake was discovered to increase if the cells had 
been pretreated with 10% dimethylsulfoxide (DMSO) for one hour prior to transfection 
(Wang et al., 2010). Other macromolecules delivered by tat include peptide nucleic acid 
(PNA), which are artificial nucleic acid-mimicking polymers. PNA was either conjugated to 
tat 48-59 using 2-aminoethoxy-2-ethoxyacetic acid as a cross-linker (Richard et al., 2003) or 
linked via a disulfide bond to a cysteine-modified tat 48-60 (Lundin et al., 2008). 
Nucleic acids, on the other hand, are mostly electrostatically carried by tat. For instance, tat 
48-60 was used to deliver reporter plasmids into HeLa cells and it was shown that its 
efficiency can be further improved by adding the SV40 NLS and a dendrimer of seven lysine 
residues (Yang et al., 2009). A short membrane active peptide, LK15 (KLLKLLLKLLLKLLK) 
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was also conjugated onto tat 49-57 and used for plasmid transfection (Saleh et al., 2010). 
Antisense oligonucleotides were linked via disulfide bonds to cysteine-modified tat 49-60 
and delivered into cells to inhibit the expression of P-glycoprotein, a transmembrane pump 
that is responsible for the multidrug resistance phenotype of tumor cells (Astriab-Fisher et 
al., 2000). siRNA has also been delivered by tat 47-57 and interestingly, photostimulation 
promoted the escape of tat complexes into the cytosol (Endoh et al., 2008). Reactive oxygen 
species produced during laser illumination was postulated to damage the endosomal 
vesicles for the enhanced cytosolic access. Finally, tat has also played the role of a helper. As 
an internalisation enhancer, tat 43-60 was displayed on the surfaces of phage particles to 
augment the delivery of plasmids encapsulated within the phages (Eguchi et al., 2001). In 
another study, tat 47-57 was used more as a NLS during the transfection of CHO cells 
(Moore et al., 2009). Unlike many other systems, the presence of serum augmented tat-
mediated transfection (Astriab-Fisher et al., 2000; Eguchi et al., 2001).    
Although tat can bring nucleic acids and other macromolecules into a cell, the pathway(s) 
which tat exploits to do so is ambiguous. There is little consensus in the literature, except for 
the observation that heparan sulphate, an anionic cell membrane glycosaminoglycan, is 
crucial for uptake (Sandgren et al., 2002; Tyagi et al., 2001). Besides being rapidly 
internalised via endocytosis (Tyagi et al., 2001), heparan sulphate is probably also involved 
in the initial binding step before internalisation (Ferrari et al., 2003). It can also act as a co-
receptor for endocytosis (Leonetti et al., 2010). Interestingly, other glycosaminoglycans such 
as chondroitin sulphate and dermatan sulphate have been ruled out in the 
binding/internalisation of full length tat 1-86 (Tyagi et al., 2001) and tat 37-57 (Leonetti et 
al., 2010), but not for the shorter tat 48-60 (Sandgren et al., 2002). 
Classical endocytosis is an energy- and ATP-dependent mechanism. For the sake of 
discussion, endocytosis can be further classified into clathrin-mediated endocytosis, 
caveolae-mediated endocytosis, macropinocytosis and other forms of clathrin- and caveolae-
independent endocytosis. Prompted by the observation that tat 48-60 was internalised at 
4°C, a temperature normally considered inhibitory for endocytosis, an energy-independent 
pathway was initially suggested to be responsible (Futaki et al., 2001b). Another group 
similarly detected low-temperature internalisation of tat 43-60 and reported that uptake was 
independent of endocytosis but required the presence of caveolae (Eguchi et al., 2001). The 
ability of free tat 47-57 to enter cells in the presence of sodium azide, which blocks 
intracellular ATP synthesis, also led the authors to preclude endocytosis as the uptake 
mechanism (Ignatovich et al., 2003).  
Several models of energy-independent uptake have been proposed. A common theme seems 
to involve the peptide sticking to the cell membrane and creating a local mass imbalance. At 
the same time, it transforms itself into a more non-polar compound either due to charge 
neutralisation (Su et al., 2009) or hydrogen bonding (Rothbard et al., 2004) with the anionic 
membrane proteins. The peptide then partitions into the hydrophobic lipid bilayer 
(Rothbard et al., 2002) and translocates through the membrane in a process that is driven by 
the voltage potential across membrane (Rothbard et al., 2004) and/or the need to relieve 
membrane curvature stress caused by the mass imbalance in the initial step (Su et al., 2009). 
In stark contrast, Richard and colleagues reported that the uptake of tat 48-59, in both its 
free and PNA-conjugated forms were sensitive to low temperature and sodium azide, 
indicative of classical endocytosis (Richard et al., 2003). Endocytosis is also believed to be 
responsible for the uptake of protein-conjugated tat 37-72 in another study (Fawell et al., 
1994). Having agreed that the uptake of tat requires energy, opinions are once again divided 
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regarding which of the specific endocytosis pathways involved. For instance, a study 
singled out clathrin-mediated endocytosis as the pathway responsible for the uptake of 
unconjugated tat 48-59 (Richard et al., 2005). In others, caveolae-mediated endocytosis was 
suggested to be the dominant form of uptake for GFP/tat 48-60 fusion protein (Ferrari et al., 
2003), and also for GFP/tat 48-58 and GFP/tat 1-86 fusion proteins (Fittipaldi et al., 2003). 
To confound matters, macropinocytosis was reported to be mainly responsible for the 
uptake of PNA-conjugated tat 48-60 (Lundin et al., 2008) and tat 48-57 fusion protein (Wadia 
et al., 2004). In yet another twist, multiple pathways involving both clathrin-mediated 
endocytosis and macropinocytosis were proposed for the internalisation of unconjugated tat 
48-60 (Räägel et al., 2009). 
With this amount of confusion in the literature, is there hope of reconciliation? It seems that 
the first step is to recognise that there may not be a single mechanism responsible for the 
uptake of tat or indeed, other CPP that will be discussed. CPP thus cannot be taken in the 
same light as transferrin (Rejman et al., 2004) or cholera toxin (Torgersen et al., 2001), which 
are accepted to be internalised exclusively via the clathrin- and caveolae-mediated pathway 
respectively in a wide variety of cells. The outcome being observed therefore depends on the 
combination of cell/peptide/detection method chosen for that experiment and 
heterogeneity in conclusion can be expected due to the following reasons. 
Cell: Different cell lines can use different pathways to internalise tat (Ignatovich et al., 2003). 
The nature of cells (primary versus immortalised or adherent versus suspension) 
(Eiriksdottir et al., 2010) and culture conditions such as the type of growth medium 
(Moulton et al., 2004), passage number of cells or even the Young’s modulus (Kong et al., 
2005) of the substrate were suggested to influence plasmid transfection and uptake.     
Peptide: As can be seen from Table 2, there are at least 12 distinct sequences under the same 
umbrella name of tat – more if one takes into account chain-end modifications. Considering 
that simply modifying a few residues can drastically affect the property of tat, as discussed 
earlier, it is understandable why the literature cannot seem to agree. The concentration of 
peptide used was also shown to be important. For instance, it was reported that below 10 
mM, unconjugated tat 47-57 exploited both macropinocytosis and caveolae-mediated 
endocytosis to gain entry but once above 10 mM, a non-endocytosis mechanism seemed to 
operate (Duchardt et al., 2007). Perhaps there is a concentration threshold above which there 
is sufficient amount of surface-bound peptide to cause the mass imbalance and trigger direct 
transport through the membrane. Finally, the absence or presence and the nature of the 
cargo can also influence the mechanism of uptake. For example, unconjugated tat 47-57 was 
reported to enter cells using an energy-independent mechanism but endocytosis was 
responsible after a plasmid was bound (Ignatovich et al., 2003). 
Detection method: The majority of experiments aimed at studying the endocytosis pathways 
of peptides uses one or both of the following techniques: 1) assaying the effects of drugs that 
are known to inhibit specific endocytosis pathways at the uptake (by flow cytometry or 
confocal microscopy) and/or the gene expression level, or 2) using a confocal microscope to 
trace for any co-localisation with known markers for endocytosis pathways, e.g., transferrin 
(clathrin), cholera toxin (caveolae) or dextran (macropinocytosis). While both are sensible 
experiments, one must also be aware of their limitations. Inhibitory drugs are usually 
pleiotropic and affect more than one pathway concurrently. For instance, dynasore has been 
used to shut down the clathrin-mediated pathway (Gratton et al., 2008a). However, 
dynasore is a drug that interferes with the activity of dynamin, an enzyme that is needed in 
both clathrin- and caveolae-mediated pathway to pinch off vesicles from the cell membrane 
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(Macia et al., 2006). The same is true for methyl-ǃ-cyclodextrin, which depletes cholesterol 
from the membrane (Richard et al., 2005) and cytochalasin, which disrupts actin formation 
(Belting et al., 2005). Both drugs can affect all three forms of endocytosis. Moreover, any 
drug that interferes with uptake is usually toxic and a safe effective dosage must be 
established in order not to affect the conclusion. There is also possible redundancy in the 
uptake mechanisms whereby shutting off one pathway may activate another (Rodal et al., 
1999), further complicating interpretation.    
Both flow cytometry and confocal microscopy are fluorescent-based techniques and rely on 
either the carrier or/and its cargo to be labelled with a dye. However, the process of tagging 
the peptide with a dye can already affect its property. For example, results from isothermal 
titration calorimetry showed that unlabelled tat 47-57 binds to heparan sulphate much more 
strongly that tat 47-57 labelled with fluorescein isothiocyanate (FITC), a florescent dye 
whose hydrophobicity has been implicated in the weakening of binding affinity (Ziegler et 
al., 2005). In another study, FITC labelling was also observed to alter the trafficking property 
of an octaarginine conjugate (Puckett & Barton, 2009). Significantly, fixing of cells has been 
shown to be undesirable and even mild fixing can cause artifactual intracellular 
accumulation (Richard et al., 2003). As a result of this revelation, the validity of earlier 
publications has been challenged, especially in studies where cells were fixed and 
intracellular accumulation could still be observed despite low temperature incubation. 
Surface-bound peptides are another source of confusion which must be separated from 
those which have been truly internalised (Richard et al., 2003). A brief trypsin wash is 
typically enough to digest and remove most of the surface-bound peptides. 
Above all, it is fair to say that our understanding of endocytosis is still not perfect. As 
mentioned earlier, it is still not clear which other pathways, besides the clathrin-mediated 
one, can produce vesicles that undergo acidification. Whether vesicles from different origin 
eventually merge is another unresolved issue. Furthermore, both the size (Choi et al., 2006) 
and shape (Sharma et al., 2010) can affect the uptake of a particle and its in vivo distribution 
(Decuzzi et al., 2010). However, these physical parameters of tat or other CPP complexes are 
seldom reported. Great care must also be taken when reporting particle sizes based on light 
scattering as a recent survey has estimated that up to 90% of the published figures can be 
erroneous due to inappropriate assumptions being made during measurements (Keck & 
Muller, 2008). With such a plethora of factors that can affect outcome, it seems more realistic 
to accept that the uptake of tat or its conjugates cannot be ascribed any particular route.   
4.3 Oligoarginine (Argn, usually n = 7 to 9) 
The potential of using arginine for gene delivery was firmly established when it was shown 
that replacing most of the arginine residues in tat 1-86 with alanine drastically reduced 
internalisation (Tyagi et al., 2001). Replacing the arginine residues within tat 48-60 with 
lysine had a similar effect and abolished internalisation (Thoren et al., 2004). Clearly, 
arginine residues are crucial. However, another important (but less obvious) message from 
these experiments is that arginine is more than just a cationic residue as replacing it with 
lysine, another cationic residue, is not good enough.    
Oligoarginine of various lengths have been evaluated. In one study, oligoarginine with 4, 6, 
8, 10, 12 or 16 residues were compared and it was found that both arg4 and arg16 were poorly 
taken up by cells (Futaki et al., 2001b). Instead, arg8 exhibited the highest rate of 
internalisation both in its free form or when linked via a disulfide bond to a model carbonic 
anhydrase protein. This demonstrated that cationic charge was not sufficient to afford 
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efficient uptake. Consistent with this, another study showed that arg7 was internalised much 
more efficiently into Jurkat cells than lys7 and his7 (Mitchell et al., 2000). There was therefore 
something unique about the chemical structure of arginine that cannot be explained simply 
by it carrying a cationic charge. Indeed, the guanidine (pKa~12) sidegroup of arginine was 
determined to be key as replacing it with a urea (pKa~0.1) sidegroup removed 
internalisation. Urea differs from guanidine by only a single nitrogen atom, which in the 
former is replaced by an oxygen atom. However, this simple modification removed not only 
the ability of urea to protonate at neutral pH, but also its ability to form hydrogen bonds. 
This ability to form stable hydrogen bonds with the anionic phosphates and sulphates on 
cell membrane was then suggested to be the feature that distinguished arginine from lysine 
and histidine in terms of translocation efficiency (Mitchell et al., 2000).  
The spacing between arginine residues can also influence internalisation (Rothbard et al., 
2002). To study this, a library of oligoarginines was synthesised, all with seven residues but 
separated by 1-6 spacers at all the possible permutations. It was argued that the addition of 
spacers imparted flexibility to the arginine backbone which was important for better 
membrane translocation.     
A length of 7-9 arginines is usually preferred and the chains exist as random coils in buffer 
solutions and when bound to lipid vesicles (Caesar et al., 2006). Both D- and L-arginines 
have been explored with some authors preferring D-arginines (Hyun et al., 2010; Puckett & 
Barton, 2009) and others finding no difference between the stereoisomers (Mitchell et al., 
2000; Nakase et al., 2004). Cargoes of different nature have been delivered. Negatively 
charged QCs were electrostatically bound to arg8 and delivered into adipose tissue-derived 
stem cells for imaging purposes (Yukawa et al., 2010). The anti-cancer drug, taxol was 
covalently bound to arg8 via disulfide bonds using a novel linker to increase its water solubility 
and uptake. The drug was also designed to be released intracellularly so as to combat 
multidrug resistant cell lines which otherwise have limited accumulation of chemotherapeutic 
drugs (Dubikovskaya et al., 2008). The immunosuppressive drug, cyclosporine A, was coupled 
with arg7 using a novel pH-sensitive linker and used for topical delivery in a skin 
inflammation model (Rothbard et al., 2000). Phosphorodiamidate morpholino oligomers 
(PMO) are antisense molecules that interfere with mRNA translation but structurally differ 
from nucleic acids in several aspects. In one study, PMO was electrostatically carried by an 
arg9-based carrier, but the efficiency was not as good as covalently linked ones (Moulton et al., 
2004). In another study, a short peptide sequence corresponding to the C-terminus of the cystic 
fibrosis transmembrane regulator was joined to arg7 during synthesis and laser illumination 
was used to trigger the release of the conjugate into the cytosol of U2OS cells (Maiolo-III et al., 
2004). siRNA was electrostatically carried by an arg8-based vector and used to transfect mouse 
bone marrow-derived dendritic cells (Akita et al., 2010). Finally, D-arg9 with cysteines added 
on both terminals (i.e., cys-arg9-cys) was crosslinked via disulfide bonds to form a mesh of 
reducible poly(oligoarginine) (Hyun et al., 2010). The carrier was then used to deliver plasmids 
encoding for heme oxygenase-1 (useful for the treatment of ischemia/reperfusion-induced 
brain stroke) by direct injection into the brain of mice. 
Several modifications have been made to oligoarginine to improve its transfection efficiency. 
For example, arg8 has been combined with GALA, a pH sensitive fusogenic peptide to enhance 
its endosomal escaping property (Akita et al., 2010). The addition of a hydrophobic stearyl 
chain to arg8 was also shown to greatly increase its transfection ability (Futaki et al., 2001a). 
This was suggested to be due to a better association between the hydrophobic moieties on the 
vector and the lipid bilayer (Putnam, 2006). Indeed, a certain degree of hydrophobicity is a 
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common feature of many efficient vectors and this was clearly shown in a recent study where 
a novel triblock peptide, phobic5-his4-arg8, was developed (Seow & Yang, 2009b; Seow et al., 
2009). This design featured a block of five hydrophobic residues (tryptophan, phenylalanine or 
isoleucine, in order of increasing hydrophobicity) for enhanced uptake, a middle block of four 
histidines for buffering capacity and a third block of arg8 for DNA binding and membrane 
penetration. Removing the hydrophobic block drastically reduced the efficiency of the carrier 
at both the uptake and gene expression level. Transfection efficiency can also be modulated 
just by changing the hydrophobicity of the hydrophobic block. The buffering capacity of the 
carriers was also assessed in a series of acid-base titration experiments and shown to vary with 
the length of the histidine block used. Each block was then systematically studied and an 
optimised sequence was used to mediate reporter plasmid expression by direct local injection 
into mice bearing 4T1 tumors. In another study, cholesterol was added as the hydrophobic end 
of a his5/10-arg10 vector for gene delivery (Guo et al., 2008).      
The internalisation of oligoarginine is sharply inhibited by the presence of heparin, which 
competes with heparan sulphate for binding (Seow et al., 2009). This shows that heparan 
sulphate is crucial for uptake. Low-temperature internalisation was observed and energy-
independence was originally proposed to characterise the uptake of oligoarginine (Futaki et 
al., 2001b). However, those observation was made with fixed cells. In response to studies 
that had exposed the flaws of using fixed cells (Richard et al., 2003), authors of the original 
study re-evaluated the uptake mechanism using live cells. Consequently, they reported 
macropinocytosis to be a major, but not exclusive pathway for the uptake of oligoarginine 
(Nakase et al., 2004). Macropinocytosis was also proposed to be the main form of uptake for 
protein-conjugated (Takayama et al., 2009) and siRNA-bound arg8 (Akita et al., 2010). 
Nonetheless, an energy-independent form of uptake was still suggested if the concentration 
of unconjugated arg9 exceeded 10 mM – otherwise, macropinocytosis and caveolae-
mediated, but not clathrin-mediated endocytosis seemed to be important (Duchardt et al., 
2007). Another study reported that both clathrin-mediated endocytosis and 
macropinocytosis play a role for the uptake of unconjugated arg9 (Räägel et al., 2009). On the 
other hand, all three forms of endocytosis (clathrin-mediated, caveolae-mediated and 
macropinocytosis) were found to be responsible for the uptake of plasmid-bound 
oligoarginine complexes (Seow et al., 2009). Finally, an energy-dependent but non-
endocytosis mechanism was also proposed to be responsible for uptake (Mitchell et al., 
2000). Like tat, there is little consensus over the internalisation pathway(s) of oligoarginine, 
although endocytosis is generally accepted to play a key role in most cases (Richard et al., 
2003; Rothbard et al., 2000). 
4.4 Penetratin 
Homeoproteins are regulatory proteins essential for proper physical development. The 
DNA binding domain of these proteins is made up of a highly conserved sequence known 
as the homeobox. The homeobox of the Drosophila antennapedia gene (pAntp) is 60-amino 
acid long (sequence 1-60) and contains three ǂ-helices (Derossi et al., 1994). pAntp was first 
discovered to effectively translocate into nerve cells and accumulate within their nuclei 
(Joliot et al., 1991). To demonstrate the usefulness of pAntp as a carrier, a 33-residue peptide 
cargo corresponding to the C-terminus of rab3, a GTP-binding protein in human, was linked 
to pAntp via plasmid fusion and shown to translocate into the nuclei of myoblasts and 
neurons (Perez et al., 1992). A study later revealed that the third helix was actually the 
domain driving internalisation (Roux et al., 1993). Based on this, penetratin, a 16-residue 
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peptide within the third helix (sequence 43-58 of the original pAntp) was described (Derossi 
et al., 1994). Penetratin demonstrated membrane penetrating ability but was prone to 
aggregation. Aggregated particles can enjoy better internalisation due to a sedimentation 
effect which promotes a more intimate particle-cell contact (Luo & Saltzman, 2000b). While 
this may have helped the internalisation of penetratin, aggregation alone was excluded as 
the dominant reason for its efficient internalisation (Derossi et al., 1994).       
The secondary structure of penetratin in buffer is unstructured but becomes ǂ-helical 
when bound to lipid vesicles (Caesar et al., 2006). Raman microscopy on live cells further 
showed that penetratin within the cytosol was either unstructured or in the ǃ-sheet 
conformation (Ye et al., 2010). The arginine residues within penetratin are important as 
replacing them with lysine greatly reduced its translocation ability (Caesar et al., 2006). 
Various cargoes have been carried by penetratin. Antisense oligonucleotides (Astriab-
Fisher et al., 2000), PNA (Lundin et al., 2008) and luciferin protein (Eiriksdottir et al., 2010) 
have all been coupled onto a cysteine-modified penetratin via disulfide bonds and 
delivered into cells. siRNA was electrostatically bound to penetratin and although the 
complexes accumulated favourably within cells, there was limited silencing activity 
(Lundberg et al., 2007). HA2 was then added to enhance endosomal escape but produced 
only a modest improvement. Penetratin has been evaluated in vivo. In one study, 
penetratin was directly injected into a rat’s brain and the peptide was observed to spread 
away from the site of injection (Bolton et al., 2000). However, dosage-dependent cell death 
and inflammatory responses were also provoked.     
Penetratin was initially suggested to enter cells using energy-independent mechanisms 
(Derossi et al., 1994; Perez et al., 1992; Roux et al., 1993), but a caveat is that fixed cells were 
used in those studies. Nonetheless, an energy-independent mechanism was still suggested 
to be possible past a concentration threshold of 40 mM, below which all three forms of 
endocytosis should dominate (Duchardt et al., 2007). Endocytosis was also reported to be 
responsible for the uptake of siRNA-bound penetratin (Lundberg et al., 2007) while 
macropinocytosis was suggested to be the main form of uptake for PNA-conjugated 
penetratin (Lundin et al., 2008).   
4.5 Transportan (Tp) and Tp10 
Tp uses a lysine residue to join the first 12 N-terminus residues of the neuropeptide, galanin, 
to the 14 C-terminus residues of the wasp venom, mastoparan. Tp is thus 27 residues long 
(sequence 1-27) and was first shown to penetrate Bowes’ melanoma cells rapidly and 
efficiently (Pooga et al., 1998). However, Tp at a high concentration was found to inhibit the 
GTPase activity of cells. To overcome this side effect, a series of Tp analogues was prepared 
(Soomets et al., 2000). This led to the identification of Tp10 which, upon deleting the first 6 
residues of Tp (i.e., sequence 7-27 remaining), was internalised as efficiently as Tp but did 
not have any effect on the GTPases.  
PNA (Lundin et al., 2008) and luciferin (Eiriksdottir et al., 2010) were conjugated to both 
cysteine-modified Tp and Tp10 via disulfide bonds. siRNA was also electrostatically bound 
to Tp10 but had little silencing effects when transfected into cells (Lundberg et al., 2007). 
This was surprising insofar as Tp10 was shown earlier to mediate good levels of plasmid 
expression. This however resonates with comments made by other researchers (Mahon et 
al., 2010; unpublished observation) who had observed that a carrier’s efficiency in plasmid 
delivery may not automatically apply to the delivery of the shorter and stiffer siRNA 
molecules. Earlier studies with fixed cells reported low temperature internalisation of Tp 
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(Pooga et al., 1998) but more recent observations have linked endocytosis to the uptake of 
both Tp and Tp10 (Lundin et al., 2008). 
4.6 Other notable peptide sequences 
VP22 is a 300-residue long peptide derived from the structural protein of HSV-1 and has 
been used successfully to deliver GFP as a fusion protein (Elliott & O’Hare, 1997). When 
COS-1 cells were microinjected with plasmids encoding for VP22, an interesting pattern was 
observed in which a central cell would first express VP22 and exhibit cytosolic staining 
when probed with anti-VP22 antibodies. The VP22 peptide was then excreted and could 
infect neighbouring cells before eventually localising to their nuclei. CADY is a 20-residue 
long peptide evaluated for siRNA delivery (Crombez et al., 2009). It changes from 
unordered to being ǂ-helical in the presence of lipid vesicles which then drives its 
internalisation independently of the endosomal pathway (Konate et al., 2010). MPG is a 27-
residue peptide designed to have a hydrophobic domain (sequence 1-17) derived from HIV 
gp41 and a NLS domain (sequence 21-27) derived from SV40 separated by a “trp-ser-gln” 
unit (Morris et al., 1997). The uptake of MPG/oligonucleotide complexes was shown to be 
rapid and independent of the endosomal pathway. Other carriers explored for delivery 
include KALA (Wyman et al., 1997) and EB1 (Lundberg et al., 2007).  
Throughout the discussion, various peptides with fusogenic and nuclear localising 
properties were introduced. SV40 is the classical NLS and different sequences exist. The 
most commonly used sequence for SV40 is provided in Table 1. Other sequences include 
“glu-asp-pro-tyr” (Trentin et al., 2005) and “glu-pro-tyr-cys” (Moore et al., 2009) being 
added onto the C-terminus and an even longer form of SV40 has been described (Eguchi 
et al., 2001). INF 5 and INF 7 are examples of two commonly used fusogenic peptide and 
both are derived from the parent HA2 peptide (Plank et al., 1994). GALA is a 30-amino 
acid long pH-sensitive fusogenic peptide (Subbarao et al., 1987).  Upon protonation of  
its glu residues, its secondary structure changes from unordered at neutral pH to being  
ǂ-helical in acidic environments. Both the amphipathicity and degree of ǂ-helicity have 
been correlated with the ability of GALA to interact and destabilise membranes (Parente 
et al., 1990).  
5. Conclusion 
This chapter started by discussing the challenges and intracellular barriers associated with 
the delivery of nucleic acids. Strategies used to overcome these hurdles were next examined, 
mainly in the context of peptide-derived vectors. It is clear that peptide carriers are not 
characterised by any typical sequences, although the majority of current designs rely on 
cationic residues to bind nucleic acids. This strategy, nonetheless, may be problematic 
during in vivo applications. An area that deserves more attention is the development of 
vectors that can bind nucleic acids using non-electrostatic forces, e.g., by including more 
hydrophobic residues. The stability and in vivo behaviour of such vectors then need to be 
thoroughly evaluated. Another challenge is to further improve strategies that are already in 
place to shield the cationic charges, e.g., by attaching PEG chains that are intracellularly 
cleavable so as to increase the circulation time of the complexes without compromising 
excessively on transfection efficiency. Advances in either will enable peptides to further 
realise their potential as a class of non-viral vector. 
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